{"title":"Mitochondria-targeted antioxidant skq1 reverses functional impairment and histopathological insults in a chronic animal model of multiple sclerosis.","authors":"Amin Zolfaghari, Ameneh Omidi, Maliheh Soodi","doi":"10.1007/s11011-025-01676-w","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple sclerosis (MS) is the most prevalent demyelinating disorder of the central nervous system (CNS), manifested by motor impairments. Due to the critical role of mitochondrial dysfunction, this study investigated the effects of the mitochondria-targeted antioxidant SkQ1 on a mouse model of MS. Animals were categorized into the control group (CONT), the cuprizone group (CPZ), and the group receiving mitochondria-targeted antioxidant SkQ1 following cuprizone (CPZ + SkQ1). After behavioral assessment, the corpus callosum underwent histopathological, biochemical, and molecular evaluations. The behavioral assessment showed a considerable motor improvement in the CPZ + SkQ1 mice compared to the CPZ group. Histopathological investigations revealed significantly higher remyelination in the corpus callosum of CPZ + SkQ1 mice than in the CPZ group. Evaluation of oxidative stress levels showed that SkQ1 administration resulted in a statistical increase in the superoxide dismutase, catalase, and total thiols but a decrease in the malondialdehyde concentration compared to the CPZ group. The relative gene expression level for myelin-related genes significantly increased in the CPZ + SkQ1 group compared to the CPZ group. The findings of this study demonstrate that mitochondria-targeted antioxidant SkQ1 may, through targeting oxidative stress in the mitochondria and consequently myelin gene expression, have induced remyelination enhancement and improved functional performance in chronic cuprizone-intoxicant mice.</p>","PeriodicalId":18685,"journal":{"name":"Metabolic brain disease","volume":"40 7","pages":"249"},"PeriodicalIF":3.5000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolic brain disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11011-025-01676-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Multiple sclerosis (MS) is the most prevalent demyelinating disorder of the central nervous system (CNS), manifested by motor impairments. Due to the critical role of mitochondrial dysfunction, this study investigated the effects of the mitochondria-targeted antioxidant SkQ1 on a mouse model of MS. Animals were categorized into the control group (CONT), the cuprizone group (CPZ), and the group receiving mitochondria-targeted antioxidant SkQ1 following cuprizone (CPZ + SkQ1). After behavioral assessment, the corpus callosum underwent histopathological, biochemical, and molecular evaluations. The behavioral assessment showed a considerable motor improvement in the CPZ + SkQ1 mice compared to the CPZ group. Histopathological investigations revealed significantly higher remyelination in the corpus callosum of CPZ + SkQ1 mice than in the CPZ group. Evaluation of oxidative stress levels showed that SkQ1 administration resulted in a statistical increase in the superoxide dismutase, catalase, and total thiols but a decrease in the malondialdehyde concentration compared to the CPZ group. The relative gene expression level for myelin-related genes significantly increased in the CPZ + SkQ1 group compared to the CPZ group. The findings of this study demonstrate that mitochondria-targeted antioxidant SkQ1 may, through targeting oxidative stress in the mitochondria and consequently myelin gene expression, have induced remyelination enhancement and improved functional performance in chronic cuprizone-intoxicant mice.
期刊介绍:
Metabolic Brain Disease serves as a forum for the publication of outstanding basic and clinical papers on all metabolic brain disease, including both human and animal studies. The journal publishes papers on the fundamental pathogenesis of these disorders and on related experimental and clinical techniques and methodologies. Metabolic Brain Disease is directed to physicians, neuroscientists, internists, psychiatrists, neurologists, pathologists, and others involved in the research and treatment of a broad range of metabolic brain disorders.